Ritlecitinib + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Stable Nonsegmental Vitiligo
Conditions
Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
Trial Timeline
Dec 1, 2022 → Feb 5, 2026
NCT ID
NCT05583526About Ritlecitinib + Placebo
Ritlecitinib + Placebo is a phase 3 stage product being developed by Pfizer for Stable Nonsegmental Vitiligo. The current trial status is completed. This product is registered under clinical trial identifier NCT05583526. Target conditions include Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07228390 | Phase 2 | Recruiting |
| NCT05636293 | Phase 2 | Recruiting |
| NCT05583526 | Phase 3 | Completed |
Competing Products
20 competing products in Stable Nonsegmental Vitiligo
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| eFT508 + Avelumab | eFFECTOR Therapeutics | Phase 2 | 44 |
| Atorvastatin 20mg loading + Atorvastatin 80mg loading | Yuhan | Approved | 85 |
| ASP7991 | Astellas Pharma | Phase 1 | 33 |
| Epoetin Alfa + Roxadustat | Astellas Pharma | Phase 3 | 77 |
| TRC041266 + Placebo | Torrent Pharmaceuticals | Phase 3 | 77 |
| Evorpacept (ALX148) + Cetuximab + Pembrolizumab | Eli Lilly | Phase 2 | 52 |
| budesonide/formoterol + formoterol | AstraZeneca | Phase 2 | 52 |
| Ticagrelor + Clopidogrel + Aspirin | AstraZeneca | Phase 2 | 52 |
| Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor) | AstraZeneca | Approved | 85 |
| TC-5214 + Placebo | AstraZeneca | Phase 1 | 33 |
| ticagrelor + clopidogrel | AstraZeneca | Phase 2 | 52 |
| Ticagrelor + Clopidogrel | AstraZeneca | Approved | 85 |
| Ticagrelor + Clopidogrel | AstraZeneca | Approved | 85 |
| grapiprant + grapiprant and pembrolizumab | Merck | Phase 1 | 33 |
| Bevacizumab + Capecitabine + Pembrolizumab | Merck | Phase 2 | 52 |
| Nicorandil + Standard Treatment | Merck | Approved | 85 |
| BPS804 + Placebo | Novartis | Phase 2 | 52 |
| CLR325 | Novartis | Phase 2 | 52 |
| Erenumab + Placebo | Amgen | Phase 2 | 51 |
| Ranolazine + Placebo | Gilead Sciences | Approved | 84 |